Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Antonio González-Martı́n, Bhavana Pothuri, Ignace Vergote, et al.
New England Journal of Medicine (2019) Vol. 381, Iss. 25, pp. 2391-2402
Open Access | Times Cited: 1778

Showing 1-25 of 1778 citing articles:

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Benjamin O. Anderson, Jame Abraham, et al.
Journal of the National Comprehensive Cancer Network (2020) Vol. 18, Iss. 4, pp. 452-478
Open Access | Times Cited: 1449
Treatment of epithelial ovarian cancer
Lindsay M. Kuroki, Saketh R. Guntupalli
BMJ (2020), pp. m3773-m3773
Open Access | Times Cited: 631
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum‐Gamez, et al.
Journal of the National Comprehensive Cancer Network (2021) Vol. 19, Iss. 2, pp. 191-226
Open Access | Times Cited: 556
PARP and PARG inhibitors in cancer treatment
Dea Slade
Genes & Development (2020) Vol. 34, Iss. 5-6, pp. 360-394
Open Access | Times Cited: 525
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Maddison Rose, Joshua T. Burgess, Kenneth J. O’Byrne, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 515
DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy
Ruixue Huang, Ping‐Kun Zhou
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 515
Targeting DNA damage response pathways in cancer
Florian J. Groelly, Matthew Fawkes, Rebecca A. Dagg, et al.
Nature reviews. Cancer (2022) Vol. 23, Iss. 2, pp. 78-94
Closed Access | Times Cited: 446
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
Rowan Miller, Alexandra Léary, Clare L. Scott, et al.
Annals of Oncology (2020) Vol. 31, Iss. 12, pp. 1606-1622
Open Access | Times Cited: 361
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Mariana Paes Dias, Sarah C. Moser, Shridar Ganesan, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 12, pp. 773-791
Closed Access | Times Cited: 359
PARP inhibitor resistance: the underlying mechanisms and clinical implications
He Li, Zhaoyi Liu, Nayiyuan Wu, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 355
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
Jonathan S. Berek, Malte Renz, Sean Kehoe, et al.
International Journal of Gynecology & Obstetrics (2021) Vol. 155, Iss. S1, pp. 61-85
Open Access | Times Cited: 320
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline
Panagiotis A. Konstantinopoulos, Barbara M. Norquist, Christina Lacchetti, et al.
Journal of Clinical Oncology (2020) Vol. 38, Iss. 11, pp. 1222-1245
Open Access | Times Cited: 282
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 3, pp. 609-617
Open Access | Times Cited: 281
The forefront of ovarian cancer therapy: update on PARP inhibitors
Mansoor Raza Mirza, Robert L. Coleman, Antonio González-Martı́n, et al.
Annals of Oncology (2020) Vol. 31, Iss. 9, pp. 1148-1159
Open Access | Times Cited: 277
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
Kathleen N. Moore, Michael A. Bookman, Jalid Sehouli, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 17, pp. 1842-1855
Open Access | Times Cited: 273
Ovarian Cancer Immunotherapy and Personalized Medicine
Susan Morand, Monika Devanaboyina, Hannah Staats, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 12, pp. 6532-6532
Open Access | Times Cited: 249
Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment
Katherine C. Kurnit, Gini F. Fleming, Ernst Lengyel
Obstetrics and Gynecology (2020) Vol. 137, Iss. 1, pp. 108-121
Open Access | Times Cited: 245
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
Bradley J. Monk, Christine Parkinson, Myong Cheol Lim, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 34, pp. 3952-3964
Open Access | Times Cited: 244
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
William P. Tew, Christina Lacchetti, Annie Ellis, et al.
Journal of Clinical Oncology (2020) Vol. 38, Iss. 30, pp. 3468-3493
Open Access | Times Cited: 240
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
Kathleen N. Moore, Amit M. Oza, Nicoletta Colombo, et al.
Annals of Oncology (2021) Vol. 32, Iss. 6, pp. 757-765
Open Access | Times Cited: 207
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
Heng Zhu, Miaoyan Wei, Jin Xu, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 203
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database
Pierre‐Marie Morice, Alexandra Léary, Charles Dolladille, et al.
The Lancet Haematology (2020) Vol. 8, Iss. 2, pp. e122-e134
Closed Access | Times Cited: 198
Biomarker-Guided Development of DNA Repair Inhibitors
James M. Cleary, Andrew J. Aguirre, Geoffrey I. Shapiro, et al.
Molecular Cell (2020) Vol. 78, Iss. 6, pp. 1070-1085
Open Access | Times Cited: 195
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
Debyani Chakravarty, Amber M. Johnson, Jeffrey Sklar, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 11, pp. 1231-1258
Open Access | Times Cited: 171
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
Stéphanie Lheureux, Mihaela Cristea, Jeffrey P. Bruce, et al.
The Lancet (2021) Vol. 397, Iss. 10271, pp. 281-292
Open Access | Times Cited: 168
Page 1 - Next Page

Scroll to top